Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000883213
Ethics application status
Approved
Date submitted
6/10/2009
Date registered
9/10/2009
Date last updated
12/01/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Prospective observational longitudinal registry of patients with stable coronary artery disease
Scientific title
Prospective observational longitudinal registry of patients with stable coronary artery disease
Secondary ID [1] 283789 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
CLARIFY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease 251964 0
Condition category
Condition code
Cardiovascular 252150 252150 0 0
Coronary heart disease

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Observation of standard management of coronary artery disease patients over a 5 year period. Observations will be recorded at baseline and then every 12 months for 5 years. Data will be recorded detailing; patient demographics, cardiovascular risk factors, medical history, physical status (height, weight, electrocardiogram, blood test results for lipids and glucose) and current medications.
Intervention code [1] 241378 0
Not applicable
Comparator / control treatment
No treatment
Control group
Uncontrolled

Outcomes
Primary outcome [1] 253022 0
To characterise contemporary coronary artery disease (CAD) patients in terms of; demographic characteristics, clinical profiles and management and outcomes to identify gaps between treatment and evidence
Timepoint [1] 253022 0
5 years after recruitment
Secondary outcome [1] 257835 0
To determine the long term prognostic determinants in this population, including resting heart rate (measured using an electrcardiogram), with a view to developing a risk prediction model. A statistic regression model will be used to determine the factors with prognostic importance.
Timepoint [1] 257835 0
5 years after recruitment

Eligibility
Key inclusion criteria
Outpatients with stable coronary artery disease proven by history of at least one of the following criteria:
- documented myocardial infarction (>3months ago)
- coronary angiography showing at least one coronary stenosis of more than 50%
- chest pain with myocardial ischaemia proven by stress electrocardiogram, stress echocardiography or myocardial imaging
- coronary artery bypass graft or percutaneous coronary intervention (>3 months ago)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients hospitalised for cardiovascular disease within last 3 months (including revascularisation)
- Patients with planned revascularisation
- Conditions hampering participation in the 5 year follow up, such as limited cooperation, limited legal capacity, serious non-cardiovascular disease or conditions interfering with life expectancy (cancer, drug abuse etc) or severe cardiovascular disease (advanced heart failure, severe valve disease, history of valve repair/replacement etc)

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/12/2009
Actual
18/02/2010
Date of last participant enrolment
Anticipated
Actual
28/06/2010
Date of last data collection
Anticipated
Actual
30/09/2015
Sample size
Target
30000
Accrual to date
Final
32703
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment outside Australia
Country [1] 2222 0
France
State/province [1] 2222 0
Country [2] 2223 0
Austria
State/province [2] 2223 0
Country [3] 2224 0
Belgium
State/province [3] 2224 0
Country [4] 2225 0
Denmark
State/province [4] 2225 0
Country [5] 2226 0
Finland
State/province [5] 2226 0
Country [6] 2227 0
Germany
State/province [6] 2227 0
Country [7] 2228 0
Greece
State/province [7] 2228 0
Country [8] 2229 0
Ireland
State/province [8] 2229 0
Country [9] 2230 0
Italy
State/province [9] 2230 0
Country [10] 2231 0
Netherlands
State/province [10] 2231 0
Country [11] 2232 0
Portugal
State/province [11] 2232 0
Country [12] 2233 0
Spain
State/province [12] 2233 0
Country [13] 2234 0
Switzerland
State/province [13] 2234 0
Country [14] 2235 0
United Kingdom
State/province [14] 2235 0
Country [15] 2236 0
Bulgaria
State/province [15] 2236 0
Country [16] 2237 0
Czech Republic
State/province [16] 2237 0
Country [17] 2238 0
Hungary
State/province [17] 2238 0
Country [18] 2239 0
Latvia
State/province [18] 2239 0
Country [19] 2240 0
Poland
State/province [19] 2240 0
Country [20] 2241 0
Romania
State/province [20] 2241 0
Country [21] 2242 0
Russian Federation
State/province [21] 2242 0
Country [22] 2243 0
Slovakia
State/province [22] 2243 0
Country [23] 2244 0
Slovenia
State/province [23] 2244 0
Country [24] 2245 0
Ukraine
State/province [24] 2245 0
Country [25] 2246 0
United States of America
State/province [25] 2246 0
Country [26] 2247 0
Canada
State/province [26] 2247 0
Country [27] 2248 0
Argentina
State/province [27] 2248 0
Country [28] 2249 0
Brazil
State/province [28] 2249 0
Country [29] 2250 0
Mexico
State/province [29] 2250 0
Country [30] 2251 0
Saudi Arabia
State/province [30] 2251 0
Country [31] 2252 0
South Africa
State/province [31] 2252 0
Country [32] 2253 0
China
State/province [32] 2253 0
Country [33] 2254 0
Korea, Democratic People's Republic Of
State/province [33] 2254 0
Country [34] 2255 0
Malaysia
State/province [34] 2255 0
Country [35] 2256 0
Singapore
State/province [35] 2256 0
Country [36] 2257 0
Thailand
State/province [36] 2257 0

Funding & Sponsors
Funding source category [1] 243839 0
Commercial sector/Industry
Name [1] 243839 0
Servier Laboratories Australia Pty Ltd
Country [1] 243839 0
Australia
Primary sponsor type
Individual
Name
Philippe Gabriel Steg
Address
Depatement de Cardiologie
Centre Hospitalier Bichat-Claude Bernard
46 rue Henri-Huchard
75018 Paris
Country
France
Secondary sponsor category [1] 237185 0
Individual
Name [1] 237185 0
Kim Fox
Address [1] 237185 0
Imperial College London,
South Kensington Campus,
London SW7 2AZ
Country [1] 237185 0
United Kingdom
Secondary sponsor category [2] 237186 0
Individual
Name [2] 237186 0
Roberto Ferrari
Address [2] 237186 0
Sant'Anna University Hospital of Ferrara, C.so Giovecca 203, 44100,
Ferrara
Country [2] 237186 0
Italy
Secondary sponsor category [3] 237187 0
Individual
Name [3] 237187 0
Ian Ford
Address [3] 237187 0
e-Science Hub
Kelvin Building
Glasgow G12 8QQ
Country [3] 237187 0
United Kingdom
Secondary sponsor category [4] 237188 0
Individual
Name [4] 237188 0
Michael Tendera
Address [4] 237188 0
Cardiology Division,
Medical University of Silesia,
Katowice
Country [4] 237188 0
Poland
Secondary sponsor category [5] 237189 0
Individual
Name [5] 237189 0
Jean Claude Tardif
Address [5] 237189 0
Montreal Heart Institute
5000, Belanger Street
Montreal, Quebec H1T 1C8
Country [5] 237189 0
Canada
Other collaborator category [1] 888 0
Individual
Name [1] 888 0
Assoc/Prof Chris Reid
Address [1] 888 0
Faculty of Medicine Nursing and Health Sciences
3rd Floor, Burnet Building, AMREP
89 Commercial Rd
Melbourne Vic 3004
Country [1] 888 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 243964 0
Bellberry Ltd
Ethics committee address [1] 243964 0
229 Greenhill Rd
Dulwich SA 5065
Ethics committee country [1] 243964 0
Australia
Date submitted for ethics approval [1] 243964 0
28/10/2009
Approval date [1] 243964 0
30/11/2009
Ethics approval number [1] 243964 0

Summary
Brief summary
CLARIFY is an international, observational, longitudianl registry in stable coronary artery disease outpatients with 5 year follow up. The registry will improve knowledge surrounding the care of outpatients with coronary artery disease.
Trial website
www.clarify-registry.com
Trial related presentations / publications
CLARIFY Registry Bibliography
Global publications
1. Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG, for the CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Published Online August 30, 2016 http://dx.doi.org/10.1016/S0140-6736(16)31326-5
2. Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY Registry. PloS One 2015; 10(4):e0125164. doi: 10.1371/journal.pone.0125164
3. Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox K, Hu D, Shalnova S, Steg PG, on behalf of the CRI. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry. Eur J Prev Cardiol 2014. doi: 10.1177/2047487314547652
4. Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG, Hu D, Tendera M, Tardif, for the CLARIFY Investigators. Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. Int J Cardiol. 2013 Sep 10;167(6):2938-43. doi: 10.1016/j.ijcard.2012.08.013
5. Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari I, Tardif J-C, Tendera M, Greenlaw N, Steg PhG, for the CLARIFY Investigators. Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,560 Patients. PLoS One 2014 Jul 22;9(7):e102335. doi: 10.1371/journal.pone.0102335
6. Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendera M, Reid CM, Danchin N, Stepinska J, Steg PG and Fox KM. Hemoglobin and change in hemoglobin status predict mortality, cardiovascular events, and bleeding in stable coronary artery disease. Am J Med. 2017;130:720-730.
7. Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif JC, Morais J, Gamba MA, Kaab S and Tendera For The Clarify Investigators M. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. Pol Arch Intern Med. 2017;127:107-114. doi: 10.20452/pamw.3902.
8. Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG and CLARIFY Investigators. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol. 2017. DOI: 10.1002/clc.22730
9. Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J 2009; 11 (suppl D):D13–D18.
10. Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif J-C, Tendera M, Abergel H, Fox KM, for the CLARIFY Investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 2012;7(5):e36284. doi: 10.1371/journal.pone.0036284
11. Steg PG, Greenlaw N, Tendera M, Tardif J-C, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM, on behalf of the CLARIFY Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the international observational CLARIFY Registry. JAMA Intern Med. 2014. doi: 10.1001/jamainternmed.2014.3773
12. Steg PhG, Greenlaw N, Tardif J-C, Tendera M, Ford I, Kääb S, Abergel H, Fox KM, Ferrari R, on behalf of the CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Euro Heart J 2012 Nov;33(22):2831-40. doi: 10.1093/eurheartj/ehs289.
13. Tendera M, Fox K, Ferrari R, Ford I, Greenlaw N, Abergel H, Macarie C, Tardif JC, Vardas P, Zamorano J, Steg PG, for the CLARIFY Registry Investigators. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol. 2014;176(1):119-124. doi: 10.1016/j.ijcard.2014.06.052

Local publications
14. Alcocer-Gamba MA, Martinez-Sanchez C, Verdejo-Paris J, Ferrari R, Fox K, Greenlaw N, Steg PG, for the CLARIFY Investigators. Heart rate and use of beta-blockers in Mexican stable outpatients with coronary artery disease. Arch Cardiol Mex 2015 Apr 24. pii: S1405-9940(15)00027-0. doi: 10.1016/j.acmx.2015.01.004.
15. Balode I, Mintale I, Latkovskis, Jegere S, Narbute I, Bajare I, Greenlaw N, Steg PG, Ferrari R, Erglis A, for the CLARIFY Registry Investigators. Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Kaunas). 2014;50(5):295-302. doi: 10.1016/j.medici.2014.10.005.
16. CLARIFY registry launched in South Africa. Cardiovascular journal of Africa 2010;21:170.
17. Danchin N, Ferrieres J, Guenound M, Cattan S, Rushton-Smith SK, Greenlaw N, Ferrari R, Steg PG, on behalf of the CLARIFY Investigators. Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry. Arch Cardiovasc Diseases 2014;S1875-2136(14)00126-0. doi: 10.1016/j.acvd.2014.06.001
18. Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG and investigators Cr. Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry. Medicina (Kaunas). 2015;51:240-6.
19. Gandhi S, Dorian P, Greenlaw N, et al. Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. Canadian J Cardiol 2014;30:132-7. doi: 10.1016/j.ijcard.2012.08.013. 10.1016/j.cjca.2013.07.680
20. Kau LU, Dalal J, Gupta R, Natarajan S, Saran RK. ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) – Global vs. Indian cohort. Indian Heart Journal 2015:76:S44
21. Lang IM, Badr-Eslam R, Greenlaw N, Young R and Steg PG. Management and clinical outcome of stable coronary artery disease in Austria: Results from 5 years of the CLARIFY registry. Wien Klin Wochenschr, 2017. 10.1007/s00508-017-1248-1
22. Pozzoli M, Tavazzi L. [Geographical differences in clinical characteristics and management of stable outpatients with coronary artery disease: comparison between the Italian and international population included in the Worldwide CLARIFY registry.] G Ital Cardiol (Rome). 2014;15(4):226-32. doi: 10.1714/1497.16499.[Article in Italian]
23. Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg PG, Fox KM, Greenlaw N, Ferrari R, Vardas PE. Clinical Presentation and Management of Stable Coronary Artery Disease: Insights from the International Prospective CLARIFY Registry - Results from the Greek National Cohort. Hellenic J Cardiol 2014;55(6):442-7.
24. Sbarouni E, Voudris V, Georgiadou P, Hamilos, M. Steg, G, Fox, KM, Greenlaw N, Vardas PE. Heart rate and B-blockade in stable coronary artery disease in Greece. Hellenic J Cardiol 2015;56:112-7.
25. Shalnova SA, Oganov RG, on behalf of the CLARIFY Registry Investigators. [Five year dynamics of main clinical symptoms in patients with ischemic heart disease in Russia in comparison with other countries (the CLARIFY Registry)]. Kardiologiia 201717-22.
26. Shal'nova SA, Oganov RG, Steg PG, Ford I. [Coronary artery disease in Russia: todays reality evidenced by the international CLARIFY registry]. Kardiologiia 2013;53:28-33
27. Stepinska J, Marona M, Greenlaw N, Steg G. Heart rate and the use of beta-blockers in stable outpatients with coronary artery disease: Polish baseline results of the CLARIFY registry. Kardiol Pol 2014;72(11):1156-64. doi: 10.5603/KP.a2014.0134
28. Sun YH, Yu JM, Hu DY, Investigators of CLARIFY. [Status of beta-blocker use and heart rate control in Chinese patients with stable coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2016;44:19-26. DOI: 10.3760/cma.j.issn.0253-3758.2016.01.006
29. Zamorano, JL, García-Moll X, Ferrari R, Greenlaw N. Demographic and Clinical Characteristics of Patients With Stable Coronary Artery Disease: Results From the CLARIFY Registry in Spain. Revista Española de Cardiología (English Edition) Rev Esp Cardiol (Engl Ed). 2014;67(7):538-544. DOI: 10.1016/j.rec.2013.10.020.

Abstracts: global data
ESC 2017 (Barcelona, Spain, 25-30 Aug 2017)
1. Vidal-Petiot E, Greenlaw N, Ford I, Ferrari R, Fox KM, Tardif JC, Tendera M, Parkhomenko A, Bhatt DL, Steg PG, for the CLARIFY Investigators. How can we explain the J curve in hypertensive patients with coronary artery disease? An analysis of 22,672 patients from the CLARIFY registry. Hot Line: Late-Breaking Registry Results 2. 29 Aug 2017
2. Wakili R, Rizas K, Greenlaw N, Steg PG, Kaeaeb K. Antithrombotic treatment in patients with stable CAD and AF - 5-year follow-up data from the CLARIFY registry. Eur Heart J 38; suppl_1, 1 August 2017, ehx504.2862, https://doi.org/10.1093/eurheartj/ehx504.2862

ESC 2016 (Rome, Italy, 27-31 Aug 2016)
3. Steg PG, Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, for the CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Registry Hotline presentation, 30 Aug 2016
4. Tardif JC, Greenlaw N, Fox K, Ford I, Ferrari R, Morais J, Parkhomenko A, Tendera M, Steg PG. On behalf of the CLARIFY investigators. Impact of smoking status on outcomes in stable coronary artery disease: an analysis of 32 499 patients from the CLARIFY registry. Euro Heart J 2016:37 (Abstract Supplement), 170-171

5. Udell J, Gandhi S, Greenlaw N, Ford I, Jang Y, Alcocer Gamba M, Fox K, Tardif JC, Tendera M, Dorian P, Steg PG, Goodman S, on behalf of the CLARIFY investigators. Living alone and its effect on cardiovascular health: insights from the CLARIFY registry. Euro Heart J 2016:37 (Abstract Supplement), 1396-1397

ESC 2015 (London, UK, 29 Aug – 2 Sept 2015)
6. Tendera M, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif JC, Steg PG, on behalf of CLARIFY Registry Investigators. Differences in outcomes in stable CAD patients managed by cardiologists vs non-cardiologists. Data from the international prospective CLARIFY registry in 32468 patients. Registry Hotline presentation, 1 Sept 2015


ESC 2013 (Amsterdam, Netherlands, 31 Aug-4 Sept 2013)
7. Steg PG, Al-Zaibag M, Dorian P, Ferrari R, Ford I, Fox KM, Greenlaw N, Hu D, Shalnova S, Sokn FJ, Tardif JP, Tendera M, for the CLARIFY Investigators. On behalf of the CLARIFY investigators Impact of anginal symptoms and myocardial ischemia on clinical outcomes in stable CAD. Two-year results of the CLARIFY registry. 3 Sept 2013. Registry Hot Line.
8. Fauchier L, Greenlaw N, Ferrari R, Ford I, K Fox, JC Tardif, M Tendera, PG Steg, for the CLARIFY Investigators. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. Data from the international CLARIFY registry. 31 Aug 2013
9. Ferrari R, Ford I, Greenlaw N, Tardif J-C, Tendera M, Abergel H, Fox KM, Hu D, Shalnova S, Lutai M, Parkhomenko O, César LM, Mattos MA , Al-Zaibag M, Steg PG, on behalf of the CLARIFY registry investigators. Geographic variations in prevalence and management of cardiovascular risk factors in 33 283 outpatients with CAD: data from the contemporary CLARIFY registry from 45 count. 2 Sept 2013. Rapid Fire abstract

ACC 2013 (San Francisco, USA, 9–1 March 2013)
10. Kalra P, Garcia-Moll X, Zamorano J, Fox KM, Ford I, Ferrari R, Tardif J-C, Tendera M, Greenlaw N, Steg PhG. The impact of chronic kidney disease on use of evidence based therapy in stable coronary artery disease: a prospective analysis of 22 560 patients.

ESC 2012 (Munich, Germany, 25–29 August 2012)
11. Steg Ph, for the CLARIFY Investigators. Women and men with stable coronary artery disease have similar cardiovascular outcomes: observations from an international prospective cohort of 30 977 patients from 45 countries. Clinical Registry Update session. A128. 26 August 2012.
12. Tardif J-C, Ford I, Greenlaw N, Ferrari R, Tendera M, Abergel H, Fox KM, Shalova S, Steg PhG. Influence of age on the clinical characteristics, treatments and 1-year outcomes of outpatients with stable coronary artery disease: a prospective analysis of 30 978 patients. P5781. 29 August 2012.

EuroPRevent (Dublin, Ireland, 3–5 May 2012)
13. Ferrari R, Steg PG, Ford I, Greenlaw N, Tardif J-C, Tendera M, Abergel H, Fox KM. Gender differences in clinical presentation and management of outpatients with stable coronary artery disease: baseline characteristics of the CLARIFY registry.

ESC 2012 (Munich, Germany, 25–29 August 2012)
14. Ferrari R, Ford I, Fox KM, Greenlaw N, Abergel H, Kääb S, Tardif J-C, Tendera M, Steg PhG, on behalf of the CLARIFY registry investigators. Women and men with stable coronary artery disease have similar cardiovascular outcomes: observations from an international prospective cohort of 30 977 patients from 45 countries.
15. Tardif J-C, Ford I, Greenlaw N, Ferrari N, Tendera M, Abergel H, Fox KM, Shalnova S, Steg PhG, for the CLARIFY Investigators. Influence of age on the clinical characteristics, treatments and 1-year outcomes of outpatients with stable coronary artery disease: a prospective analysis of 30 978 patients.

ESC 2011 (Paris, France, 27–31 August 2011)
16. Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera JC, Abergel H, Fox KM. Heart rate, anginal symptoms, and use of beta-blockers in stable coronary artery disease outpatients. The CLARIFY registry. Monday 29 Aug 2011. A2092
17. Tardif JC, Ford I, Greenlaw N, Ferrari R, Tendera M, Abergel H, Fox KM, Steg PhG. Age differences in clinical presentation and management of outpatients with stable coronary artery disease: baseline characteristics of the CLARIFY registry. Sunday 28 Aug 2011. P679

Abstracts: national data
1. Gandhi S, Dorian P, Tardif JC, Steg PG, Huynh T, Wong GC, Love MP, Jervis K, Goodman SG, for the (ProspeCtive observational LongitudinAl Registry oF patients with stable coronary arterY Disease) CLARIFY Registry Investigators. How do Canadian patients with stable coronary artery disease compare to the rest of the world? A description of secondary prevention targets in the prospective observational longitudinal registry of patients with stable coronary artery disease (CLARIFY) registry. Can J Cardiol 2012;28(5) Suppl:S224-S225. Canadian Cardiovascular Congress (Toronto, Canada, 27–31 October 2012).
2. Gandhi S, Dorian P, Tardif JC, Steg PG, Huynh T, Wong GC, Love MP, Jervis K, Goodman SG, for the (ProspeCtive observational LongitudinAl Registry oF patients with stable coronary arterY Disease) CLARIFY Registry Investigators. High use of guideline-recommended therapies in Canadian outpatients with stable coronary artery disease: insights from the prospective observational longitudinal registry of patients with stable coronary artery disease (CLARIFY) registry. Can J Cardiol 2012;28(5) Suppl:S390-S391. Canadian Cardiovascular Congress (Toronto, Canada, 27–31 October 2012).
3. Kääb S, Sinner MF, Martens E, Goss F, Ferrari F, Fox KM, Steg PG, in Zusammenarbeit mit der Studiengruppe CLARIFY. Herzfrequenz und Therapie mit Betablocker bei stabilen amulanten Patienten mit Koronarer Herzkrankheit in Deutschland aus dem CLARIFY-Register. Clin Res Cardiol 101, Suppl 2, October 2012, P504, DOI 10.1007/s00392-012-0505-6. German Cardiac Society 2012.
4. Kääb S, Sinner MF, Goss F, Greenlaw N, Ford I, Ferrari R, Fox KM, Steg PG, für die CLARIFY Investigators. Analyse des Managements von stabilen ambulanten KHK-Patienten in Deutschland nach einem Jahr Follow-up. Internisten Volumen 55(1), Supplement March 2014, P205. Deutschen Gesellschaft für Innere Medizine e. V. (DGIM) (Wiesbaden, Germany, 26–29 April 2014)
5. Kääb S, Sinner MF, Martens E, Goss F, Greenlaw N, Ford I, Ferrari R, Fox KM, Steg PG, on behalf of CLARIFY. Management von stabilen ambulanten KHK-Patienten in Deutschland im geographischen und internationalen Vergleich – Daten aus dem CLARIFY-Register. Clin Res Cardiol 102, Suppl 1, April 2013, P474, DOI 10.1007/s00392-013-1100-1. German Cardiac Society (Deutsche Gesellschaft für Kardiologie – Herz, Mannheim, Germany, 3–6 April 2013).
6. Morais, J, Greenlaw N, Ford I, Ferrari R, Tardif J-C, on behalf of the Portuguese Investigators of CLARIFY Registry. Clinical characteristics of patients with stable coronary artery disease in Portugal. Data from the international CLARIFY Registry. Portuguese Congress of Cardiology 2012.
7. Morais, J, Greenlaw N, Ford I, Fox KM, Steg PhG, Tendera M, on behalf of the Portuguese Investigators of CLARIFY Registry. Heart rate in patients with stable coronary artery disease in Portugal. Insights from the international CLARIFY Registry. Portuguese Congress of Cardiology 2012.
8. Reid CM, Shiel L, Jelinek M, Freedman B, Hocking B, Aylward P, Hamilton-Craig I, Hargreaves A, Steg PhG, Ford I, Fox K, on behalf of the CLARIFY Registry Investigators. Clinical Presentation and Management of Outpatients with Stable Coronary Artery Disease – Australian Baseline Characteristics of the CLARIFY Registry. Heart Lung Circ 2012;21:S33.
9. Reid CM, Shiel L, Jelinek M, Freedman B, Hockings B, Aylward P, Hamilton-Craig I, Steg P, Ford I, Fox K. Clinical outcomes for patients with stable coronary artery disease in Australia - findings from the CLARIFY registry. Heart Lung Circ 2015;24(Supp.3):S141.
Public notes

Contacts
Principal investigator
Name 30358 0
A/Prof Chris Reid
Address 30358 0
The Alfred Centre
6th Floor, 99 Commercial Road
Melbourne VIC 3004
Australia
Country 30358 0
Australia
Phone 30358 0
+ 61 3 9903 0050
Fax 30358 0
Email 30358 0
[email protected]
Contact person for public queries
Name 13605 0
Ms Louise Shiel
Address 13605 0
Monash University
Caulfield Hospital
Grd Floor, Fethers Block
260 Kooyong Rd
Caulfield VIC 3162
Country 13605 0
Australia
Phone 13605 0
+61 3 9076 6169
Fax 13605 0
Email 13605 0
[email protected]
Contact person for scientific queries
Name 4533 0
Ms Louise Shiel
Address 4533 0
Monash University
Caulfield Hospital
Grd Floor, Fethers Block
260 Kooyong Rd
Caulfield VIC 3162
Country 4533 0
Australia
Phone 4533 0
+61 3 9076 6169
Fax 4533 0
Email 4533 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.